ROLFE LINDSEY (See Remarks) sold 2.3% of their position (2.54K shares) of CLOVIS ONCOLOGY, INC. on the open market
Open‑market sale worth $3.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/6/2022ACC: 0000899243-22-030421
Officer· See Remarks
Since Sep 2018
+7.58K
Net shares
Net buyer
$3.1K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10.13K acquired · 2.54K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+5.06K
Price / share
—
Trade value
—
% of position
4.7%
9/1/2022
107.06K→112.12K
Common Stock
Direct
Shares
−2.54K
Price / share
$1.20
Trade value
$3.05K
% of position
2.3%
9/2/2022
112.12K→109.58K
Total
Net shares
+2.52K
Net value
-$3.05K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/1/2022 | M · Option Exercise | +5.06K | — | — | 4.7% | 107.06K | 112.12K |
| Common Stock Direct | 9/2/2022 | S · Sale | −2.54K | $1.20 | $3.05K | 2.3% | 112.12K | 109.58K |
| Total | +2.52K | -$3.05K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
5.06K shares
Shares
+5.06K
Strike price
Held after
50.63K
Exercisable
—
9/1/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock5.06K shares | 9/1/2022 | M · Option Exercise | +5.06K | — | 50.63K |